AFP and Cirrhosis: Studies have pointed out that the level of circSMARCA5 can effectively distinguish patients with liver cancer hepatitis and liver fibrosis rom healthy controls, and it is also meaningful in patients with hepatitis and cirrhosis with AFP < 200 ng/ml.